INDIANAPOLIS, Dec. 8, 2023 /PRNewswire/ -- The board of
directors of Eli Lilly and Company (NYSE: LLY) has announced a 15%
increase in its quarterly dividend and declared a dividend for the
first quarter of 2024 of $1.30 per share on outstanding
common stock.
The dividend is payable on March 8, 2024 to shareholders of
record at the close of business on Feb. 15, 2024.
About Lilly
Lilly unites caring with discovery to
create medicines that make life better for people around the world.
We've been pioneering life-changing discoveries for nearly 150
years, and today our medicines help more than 51 million
people across the globe. Harnessing the power of biotechnology,
chemistry and genetic medicine, our scientists are urgently
advancing new discoveries to solve some of the world's most
significant health challenges, redefining diabetes care, treating
obesity and curtailing its most devastating long-term effects,
advancing the fight against Alzheimer's disease, providing
solutions to some of the most debilitating immune system disorders,
and transforming the most difficult-to-treat cancers into
manageable diseases. With each step toward a healthier world, we're
motivated by one thing: making life better for millions more
people. That includes delivering innovative clinical trials that
reflect the diversity of our world and working to ensure our
medicines are accessible and affordable. To learn more,
visit Lilly.com and Lilly.com/news. F-LLY
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements (as that term is defined in the Private Securities
Litigation Reform Act of 1995) about expected dividend payments and
reflects Lilly's current beliefs and expectations. However, there
are significant risks and uncertainties in pharmaceutical research
and development, as well as in business development activities and
capital allocation strategies related to the company's business and
actual results may differ materially due to various factors. For
further discussion of risks and uncertainties relevant to Lilly's
business that could cause actual results to differ from Lilly's
expectations, see Lilly's Form 10-K and Form 10-Q filings with the
United States Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements to reflect events after the date of this release.
Refer
to:
|
|
Jordan
Bishop; jordan.bishop@lilly.com; 317-473-5712
(Media)
|
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-announces-15-dividend-increase-first-quarter-2024-dividend-302010271.html
SOURCE Eli Lilly and Company